Anti cd8 2.43

Manufactured by BioXCell

Sourced in United States

The Anti-CD8 (2.43) is a monoclonal antibody that binds to the CD8 receptor on T cells. It is a research-use-only product intended for experimental applications.

Automatically generated - may contain errors

Lab products found in correlation

9 protocols using anti cd8 2.43

Evaluating APR-246 and Immunotherapies in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

APR-246 was provided by Aprea Therapeutics under a material transfer agreement. APR-246 was reconstituted in PBS just prior to injection and used at 100 mg/kg per mouse administered intraperitoneally (i.p.) daily as depicted in respective experiments; PBS was used as vehicle control. Therapeutic in vivo monoclonal antibodies (mAbs) anti–PD-1 (RMP1-14) and anti–CTLA-4 (9D9), corresponding IgG isotype controls (2A3 and MPC-11), and depleting mAbs anti-CD4 (GK1.5) and anti-CD8 (2.43) and their IgG isotype controls (LTF-2) were purchased from Bio X Cell. RMP1-14 (250 μg) and 2A3 (250 μg) were administered i.p. twice weekly beginning on day 7 for up to 4 doses. Depleting mAbs GK1.5 (560 μg) and 2.43 (400 μg) were administered i.p. twice weekly beginning on day 7 for 4 doses.

Ghosh A., Michels J., Mezzadra R., Venkatesh D., Dong L., Gomez R., Samaan F., Ho Y.J., Campesato L.F., Mangarin L., Fak J., Suek N., Holland A., Liu C., Abu-Akeel M., Bykov Y., Zhong H., Fitzgerald K., Budhu S., Chow A., Zappasodi R., Panageas K.S., de Henau O., Ruscetti M., Lowe S.W., Merghoub T, & Wolchok J.D. (2022). Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. The Journal of Clinical Investigation, 132(18), e148141.

+ Open protocol

+ Expand

T Cell Depletion and Egress Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols

To deplete T cells, mice were intraperitoneally (i.p.) injected with 400ug anti-CD4 GK1.5 or anti-CD8 2.43 (BioXcell) in PBS at D-1, D4, and D10 relative to infection. To block T cell egress, mice were i.p. injected with 1mg/kg FTY720 (Sigma) in water daily starting 2d prior to harvest.

Delahaye J.L., Gern B.H., Cohen S.B., Plumlee C.R., Shafiani S., Gerner M.Y, & Urdahl K.B. (2019). Bacillus Calmette-Guerin-induced T cells shape Mycobacterium tuberculosis infection before reducing the bacterial burden. Journal of immunology (Baltimore, Md. : 1950), 203(4), 807-812.

+ Open protocol

+ Expand

Modulating Immune Responses in Viral Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols

Agonistic mouse anti-CD40 (clone FGK4.5/FGK45, BioXCell, Lebanon, NH, USA), anti-CD154/CD40L (MR-1, BioXCell), anti-NK1.1 (PK136, BioXCell), anti-CD19 (1D3, BioXCell), anti-IL12 (R1-5D9, BioXCell), and anti-IFNγ (XMG1.2, BioXCell) antibodies were diluted to 200 µg in PBS and administered 24 h prior to viral challenge. Anti-CD4 (YTS 177, BioXCell) and anti-CD8 (2.43, BioXCell) antibodies were diluted to 200 µg/100 µL in PBS, pooled to a total of 400 µg (200 µL), and administered 24 h prior to downstream use. Isotype IgG controls (BioXCell) were used at equivalent doses in all experiments. All antibodies were administered in a final volume of 100–200 µL via intraperitoneal (i.p.) injection. Cytokines used in this study include IL-12 (StemCell Technologies, Vancouver, CA, USA, catalog #78028.1) and IFN-γ (StemCell Technologies, catalog #78020.1), which were given at 5 µg in 100 µL of PBS via i.p. injection 24 h prior to viral challenge. For the disruption of IL-12 production, the inhibitor apilimod (MedChemExpress, Monmouth Junction, NJ, USA, catalog #HY-14644) was administered via i.p. injection at a concentration of 2.5 mg/kg. The drug was administered on day −1, day 0, and day 1 post-infection with rVSV-EBOV GP.

Rogers K.J., Richards P.T., Zacharias Z.R., Stunz L.L., Vijay R., Butler N.S., Legge K.L., Bishop G.A, & Maury W. (2023). CD40 Signaling in Mice Elicits a Broad Antiviral Response Early during Acute Infection with RNA Viruses. Viruses, 15(6), 1353.

+ Open protocol

+ Expand

Evaluating T Cell-Mediated Immunity in Viral Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols

All mouse experiments were performed at OHSU in ABSL3 laboratories in compliance with OHSU IACUC protocols. The small lab animal unit at OHSU is accredited by the Association for the Accreditation and Assessment of Laboratory Animal Care (AALAC) International. Animals were housed in ventilated racks and monitored daily by veterinary staff. C57BL/6J mice were vaccinated as indicated with MCMV delivered intraperitoneally (10⁶ PFU, i.p.), and/or AdV injected intramuscularly in the thigh (10⁸ PFU, i.m.). Mice were challenged with 10³ PFU CHIKV in a 20 μl volume in the footpad (f.p.), or they were challenged (i.m.) with 10³ or 10⁴ PFU in a 20 μl volume in the calf muscle. Footpad measurements were taken with calipers. For T cell depletion experiments, mice were administered T cell depleting antibodies diluted in PBS in a 100 μl volume (i.p.). Vaccinated groups were injected with 300 μg anti-CD4 (GK1.5, BioXCell), 300 μg anti-CD8 (2.43, BioXCell), 300 μg Rat IgG2b Isotype Control (LTF-2, BioXCell), or a combination of 300 μg anti-CD4 and 300 μg anti-CD8. T cell depletions were confirmed by flow cytometry. To confirm T cell depletions, splenocytes were stained with fluorophore-conjugated antibodies specific for mouse CD3, CD4, CD8, and CD19. Fluorescent markers were detected on an LSRII instrument (BD Pharminogen) and data was analyzed using FlowJo (TreeStar).

Broeckel R.M., Haese N., Ando T., Dmitriev I., Kreklywich C.N., Powers J., Denton M., Smith P., Morrison T.E., Heise M., DeFilippis V., Messaoudi I., Curiel D.T, & Streblow D.N. (2019). Vaccine-Induced Skewing of T Cell Responses Protects Against Chikungunya Virus Disease. Frontiers in Immunology, 10, 2563.

+ Open protocol

+ Expand

Antibody Depletion of CD4+ and CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Anti-CD4 (GK1.5) and/or anti-CD8 (2.43) (Bio X Cell, NH, USA) mAbs were administered at doses of 500 µg/mouse to prM-Env DNA vaccinated mice by the i.p. route on day -2 and day -1 prior to ZIKV challenge. Antibody depletions were >99.9% efficient as determined by flow cytometry.

Larocca R.A., Abbink P., Peron J.P., de A. Zanotto P.M., Iampietro M.J., Badamchi-Zadeh A., Boyd M., Ng’ang’a D., Kirilova M., Nityanandam R., Mercado N.B., Li Z., Moseley E.T., Bricault C.A., Borducchi E.N., Giglio P.B., Jetton D., Neubauer G., Nkolola J.P., Maxfield L.F., De La Barrera R.A., Jarman R.G., Eckels K.H., Michael N.L., Thomas S.J, & Barouch D.H. (2016). Vaccine Protection Against Zika Virus from Brazil. Nature, 536(7617), 474-478.

+ Open protocol

+ Expand

Imatinib and Flt3L-induced DC Expansion

Check if the same lab product or an alternative is used in the 5 most similar protocols

Imatinib was obtained from Novartis and dissolved in the drinking water at 600 mg/liter. For in vivo DC expansion, Flt3L (30 µg in 100 µl PBS; generously provided by Celldex) or control PBS was injected i.p. (nine daily injections). At the indicated time points, the following were administered i.p.: high molecular weight poly I:C (50 µg in 100 µl; InvivoGen) or control PBS; 250 µg anti-CD8 (2.43; Bio X Cell) or rat IgG2b (LTF-2); 1 mg anti–GM-CSF (MP1-22E9; Bio X Cell) or rat IgG2a (2A3); 100 µg anti-IL-1β (B122) or Armenian Hamster IgG (BE0091); or 500 µg loading dose and 250 µg maintenance dose anti-γδTCR (UC7-13D5) or Armenian Hamster IgG (BE0091).

Medina B.D., Liu M., Vitiello G.A., Seifert A.M., Zeng S., Bowler T., Zhang J.Q., Cavnar M.J., Loo J.K., Param N.J., Maltbaek J.H., Rossi F., Balachandran V, & DeMatteo R.P. (2019). Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity. The Journal of Experimental Medicine, 216(6), 1359-1376.

+ Open protocol

+ Expand

Antibody Depletion of CD4+ and CD8+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

+ Open protocol

+ Expand

T cell depletion impacts B16F10 metastasis

Check if the same lab product or an alternative is used in the 5 most similar protocols

In vivo depletion of CD4⁺ or
CD8⁺ T cell subsets was performed by i.p. injection of 100
μg of purified monoclonal anti-CD4 (GK1.5, BioXCell) or anti-CD8
(2.43, BioXCell) antibodies twice weekly. Control (non-depleted) mice were
treated with i.p. injection of 100 μg of nonimmune IgG isotype
control (LTF-2, BioXCell). Depleted and control mice received i.v. 2.5
× 10⁵ B16F10 cells (n = 5 per group). The number of
visible black metastatic nodules on the lung surface was manually counted 18
days post-tumor injection.

Hamaidi I., Zhang L., Kim N., Wang M.H., Iclozan C., Fang B., Liu M., Koomen J.M., Berglund A.E., Yoder S.J., Yao J., Engelman R.W., Creelan B.C., Conejo-Garcia J.R., Antonia S.J., Mulé J.J, & Kim S. (2020). Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T cells. Cell metabolism, 32(3), 420-436.e12.

+ Open protocol

+ Expand

T Cell Depletion for Virus Challenge

Check if the same lab product or an alternative is used in the 5 most similar protocols

To deplete CD4 and CD8 T cells, mice were treated with 300 μg each of anti-CD4 (GK1.5, BioXCell) and anti-CD8 (2.43, BioXCell) antibodies intravenously on day −4 and −1 before and day +2 and +4 after virus challenge, and 100 μg each of anti-CD4 and anti-CD8 antibodies intranasally on d −1 before challenge.

Oh J.E., Song E., Moriyama M., Wong P., Zhang S., Jiang R., Strohmeier S., Kleinstein S.H., Krammer F, & Iwasaki A. (2021). Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Science immunology, 6(66), eabj5129.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!